Zusammenfassung
Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.
Publikationsserver
Publizieren: oa@ur.de
0941 943 -4239 oder -69394
Dissertationen: dissertationen@ur.de
0941 943 -3904
Forschungsdaten: datahub@ur.de
0941 943 -5707